News & Events
-
June 10, 2010
Critical Path Institute’s Predictive Safety Testing Consortium Announces First-Ever Qualification Decision by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
For the first time, new biomarker tests to detect drug-induced kidney injury have been accepted by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). -
May 10, 2010
Critical Path Institute’s Predictive Safety Testing Consortium Announces Special Issue of Nature Biotechnology Dedicated to Newly Qualified Kidney Safety Biomarkers
A special May 10, 2010 issue of Nature Biotechnology (NBT) includes ten scientific publications from Critical Path Institute’s Predictive Safety Testing Consortium’s evaluation of seven kidney biomarkers for use in drug safety assessment. -
January 22, 2009
Japanese PMDA Announces First Biomarker Qualification
The unprecedented sharing of data by the industry has facilitated regulatory agencies to receive, review and approve new methods as qualified for use in drug development. The use of these new tests can now be used in laboratory research to predict the safety of experimental drugs, allowing drugs to reach the market faster and with... -
March 10, 2007
C-Path Adopts Rosetta Resolver® System for the PSTC
Rosetta Biosoftware announced today that The Critical Path Institute (C-Path) adopted the Rosetta Resolver® system for C-Path’s Predictive Safety Testing Consortium. -
November 10, 2006
New Corporate Members and Leaders for C-Path’s Predictive Safety Testing Consortium Announced
The Critical Path Institute (C-Path) today announced seven new members that have recently joined the Predictive Safety Testing Consortium (PSTC)…